IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
Summary
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and Adaptate Biotherapeutics) and Dr Inga Deakin (Molten Ventures) as Non-executive DirectorsLondon, UK, 24 January 2024 IMU Biosciences (or the Company), a techbio company revolutionising immune powered precision medicine, today announces the close of a \xa311.5 million Series A financing round. "With our technology, were building the worlds largest immune data assets across health and disease, which allows us to perform analyses with a level of depth and granularity that was previously unthinkable," said Dr Adam Laing, CEO and Co-founder of IMU Biosciences. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. "Our technology could fundamentally change how we approach patient stratification for advanced therapies, disease monitoring and diagnostics," explained Dr Tom Hayday, CSO and Co-founder of IMU Biosciences. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach.